---
document_datetime: 2026-01-08 13:38:18
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/cancidas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: cancidas-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.7704571
conversion_datetime: 2026-01-10 11:07:36.564441
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.1
  docling: 2.67.0
  docling-core: 2.58.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Cancidas

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 05/01/2026                          |                                             | SmPC and PL                      |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000315850          | PRODUCTS - C.I.z Change(s) in the SmPC, labelling or package leaflet of human medicinal products in order to adapt to a recommendation of a competent authority , e.g. a Core SmPC, following the assessment of an Urgent Safety Restriction etc. Implementation of wording agreed by the competent authority that require additional minor assessment, e.g. translations are not yet agreed upon. - Accepted C.I.z - to update section 5.1 of the SmPC with the agreed reference to the EMA website, in line with EMA's Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. In addition, the MAH took the opportunity to update the list of local representatives contact details in section 6 of the Package Leaflet for the following countries: Bulgaria, Czech Republic, Greece, Croatia, Cyprus, Hungary, Malta, The Netherlands, Austria, Poland, Portugal, Romania, Slovenia and Slovakia. Finally, in section 4.8 of the SmPC the spelling of the adverse reaction   |            |            |      |           |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------|
| PSUR / EMA/PSUR/0000268976 | - - In view of available data on caspofungin treatment failure during continuous renal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 18/09/2025 | 17/11/2025 | SmPC | Variation |

<div style=\"page-break-after: always\"></div>

|                                  | replacement therapy (CRRT) with polyacrylonitrile (PAN) membranes from the literature, spontaneous reports (including in five cases a close temporal relationship and fatal outcomes), and in view of a plausible mechanism of action (adsorption of the free drug fraction by PAN membranes leading to subtherapeutic exposure), the PRAC considers a causal relationship between caspofungin and treatment failure during CRRT with PAN membranes is at least a reasonable possibility. The PRAC concluded that the product information of products containing caspofungin should be amended accordingly.   |            |            |    |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|
| Article 61(3) / EMA/N/0000266529 | - Notification acc. Article 61(3) - Accepted Update of the package leaflet with revised contact details of local representatives and to delete 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4. Additionally, the MAH took the opportunity to make minor editorial changes in some of the translations.                                                                                                                                                                                                                                        | 24/04/2025 | 17/11/2025 | PL |